Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)



Status:Completed
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:2 - 60
Updated:4/21/2016
Start Date:November 2006
End Date:October 2015

Use our guide to learn which trials are right for you!

A Phase III Randomized, Multicenter Trial Comparing Sirolimus/Tacrolimus With Tacrolimus/Methotrexate as Graft-versus-Host Disease (GVHD) Prophylaxis After HLA-Matched, Related Peripheral Blood Stem Cell Transplantation (BMT CTN #0402)

The study is designed as a phase III, randomized, open label, multicenter, prospective,
comparative trial of sirolimus and tacrolimus versus tacrolimus and methotrexate as
graft-versus-host disease (GVHD) prophylaxis after human leukocyte antigen (HLA)-matched,
related, peripheral blood stem cell transplantation in individuals with hematologic cancer.
Participants will be stratified by transplant center and will be randomly assigned to the
sirolimus/tacrolimus or tacrolimus/methotrexate arms at a 1:1 ratio.

BACKGROUND:

Stem cell transplantation is a standard therapy for acute and chronic leukemias and
myelodysplastic disorders. A common problem that may occur after a stem cell transplant is a
condition known as GVHD. The purpose of this study is to compare two combinations of
medications to see which is better at preventing GVHD. The combinations of medications in
this study are:

- Sirolimus and tacrolimus

- Methotrexate and tacrolimus

Doctors want to know if one combination is better than the other or if they both have the
same result.

DESIGN NARRATIVE:

Participants will receive one of the two conditioning regimens described in the protocol, at
the discretion of the transplant physician. The transplant physician must choose among these
regimens prior to the participant's assignment to the GVHD prophylaxis treatment.
Conditioning regimens will vary by center, but will be the same for all participants at each
center. Stem cell donors will donate peripheral blood stem cells according to local
institutional practices. Peripheral blood stem cells will not be manipulated or T-depleted
prior to administration. Standard post-transplant care will be administered. Participants
will be randomly assigned to one of two GVHD prophylaxis regimens and will be followed for
the endpoints of interest.

Participants will be followed for 114 days post-randomization for evaluation of the primary
endpoint, with additional follow-up for 2 years after transplantation for evaluation of
secondary endpoints.

Inclusion Criteria:

- 6/6 HLA-matched sibling, defined by Class I (HLA-A and B) serologic typing (or higher
resolution) and Class II (HLA-DRBI) molecular typing, who is willing to donate
peripheral blood stem cells, and meets institutional criteria for stem cell donation.
The donor must be medically eligible to donate stem cells, according to individual
transplant center criteria. Pediatric patients for whom a pediatric sibling donor is
not anticipated to be a suitable leukapheresis candidate are not eligible.

- Karnofsky performance status of at least 70% or Lansky performance status of at least
70% for participants less than 16 years old

- For participants less than 18 years old, willing and able to take oral medications,
per the treating physician's recommendations

Exclusion Criteria:

- Prior allogeneic or autologous transplant using any hematopoietic stem cell source

- Seropositive for the human immunodeficiency virus (HIV)

- Uncontrolled bacterial, viral, or fungal infection (currently taking medication and
progression of clinical symptoms)

- Pregnant (positive serum human chorionic gonadotropin [β-HCG] test) or breastfeeding
within 4 weeks of study entry

- Kidney function: serum creatinine outside the normal range for age, or measured
creatinine clearance less than 50 mL/min/1.72m^2 within 4 weeks of study entry

- Liver function: most recent direct bilirubin, alanine aminotransferase (ALT), or
aspartate aminotransferase (AST) greater than two times the upper limit of normal
within 4 weeks of study entry

- Lung disease: in adults, forced vital capacity (FVC) or forced expiratory volume in
one second (FEV1) less than 60% of predicted value (corrected for hemoglobin); in
children, overt hypoxemia, as measured by an oxygen saturation of less than 92%
within 4 weeks of study entry

- Cardiac ejection fraction of less than 45% in adults and children, or less than 26%
shortening fraction in children within 4 weeks of study entry

- Cholesterol level greater than 500 mg/dL or triglyceride level greater than 500 mg/dL
while being treated, or not on appropriate lipid-lowering therapy within 4 weeks of
study entry

- Prior history of allergy to sirolimus

- Requires voriconazole at time of study entry

- Currently receiving another investigational drug unless cleared by the protocol
officer or protocol chair

- Participants with a history of cancer, other than resected basal cell carcinoma or
treated carcinoma in-situ. Cancer treated with curative intent for more than 5 years
previously will be allowed. Cancer treated with curative intent for less than 5 years
previously will not be allowed unless approved by the protocol officer or protocol
chair.
We found this trial at
24
sites
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1600 SW Archer Rd # M509
Gainesville, Florida 32610
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
Minneapolis, Minnesota 55455
(612) 625-5000
Univ of Minnesota With a flagship campus in the heart of the Twin Cities, and...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Boston, Massachusetts 02114
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
1500 East Duarte Road
Duarte, California 91010
626-256-HOPE (4673)
City of Hope National Medical Center City of Hope is dedicated to making a difference...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
545 Barnhill Dr
Indianapolis, Indiana 46201
(317) 274-8157
Indiana University Medical Center Indiana University Health is Indiana
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
200 Hawkins Dr,
Iowa City, Iowa 52242
866-452-8507
University of Iowa Hospitals and Clinics University of Iowa Hospitals and Clinics—recognized as one of...
?
mi
from
Iowa City, IA
Click here to add this to my saved trials
LaJolla, California 92093
?
mi
from
LaJolla, CA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Paris,
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
5150 Centre Ave
Pittsburgh, Pennsylvania 15232
(412) 647-2811
University of Pittsburgh Cancer Institute Founded in 1985, the University of Pittsburgh Cancer Institute (UPCI)...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
St. Louis, MO
Click here to add this to my saved trials
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials